 After baseline investigations, the patients ICS dose is halved or as close as possible to, but not below, 50. Patients continued on the same inhaled steroid drug and device. Patients taking a combined ICSLABA inhaler halve the dose of this, as per usual clinical practice. Other asthma medicaitons are continued unchanged. 